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GOAL: 
To validate a prototype spaceflight-compatible flow cytometer and an associated microgravity-
compatible cell staining device for medical support during long-duration space missions. Five 
KC-135 evaluations of the developed hardware were performed in FY04. 
OBJECTIVES: 
A spaceflight-compatible flow cytometer would be useful for the diagnosis of astronaut illness 
during long duration spaceflight and for conducting in-flight research to evaluate the effects of 
microgravity on human physiology. Until recently, the primary limitations preventing the 
development of a spaceflight compatible flow cytometer have been largely mechanical. Standard 
commercially available flow cytometers are large, complex instruments that use high-energy 
lasers and require significant training to operate. Standard flow cytometers function by 
suspending the particles to be analyzed inside a ‘sheath’ fluid for analysis. This requires the 
presence of several liters of sheath fluid for operation, and generates a corresponding amount of 
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 liquid hazardous waste. The particles are then passed through a flow cell which uses the fluid 
mechanical property of ‘hydrodynamic focusing’ to place the cells in single-file (laminar flow) as 
they pass through a laser beam for scanning and evaluation. Many spaceflight experiments have 
demonstrated that fluid physics is dramatically altered in microgravity (MSF [Manned Space 
Flight] Fluid Physics Data Sheet-August 1997) and previous studies have shown that sheath-fluid 
based hydrodynamic focusing may also be altered during microgravity (Crucian et al, 2000). For 
these reasons it is likely that any spaceflight compatible design for a flow cytometer would 
abandon the sheath fluid requirement. The elimination of sheath fluid would remove both the 
problems of weight associated with large volumes of liquids as well as the large volume of liquid 
waste generated. It would also create the need for a method to create laminar particle flow 
distinct from the standard sheath-fluid based method. 
The spaceflight prototype instrument is based on a recently developed commercial flow 
cytometer possessing a novel flow cell design that creates single-particle laser scanning and 
evaluation without the need for sheath-fluid based hydrodynamic focusing. This instrument also 
possesses a number of design advances that make it conditionally microgravity compatible: it is 
highly miniaturized and lightweight, uses a low energy diode laser, has a small number of 
moving parts, does not use sheath fluid and does not generate significant liquid waste. Although 
possessing certain limitations, the commercial cytometer functions operationally like a standard 
bench top laboratory flow cytometer, aspirating liquid particle samples and generating histogram 
or dot-plot data in standard ‘FCS’ file format. In its current configuration however, the cytometer 
is limited to three parameter/two-color capability (two color PMTs + forward scatter), does not 
allow compensation between colors, does not allow linear analysis and is operated by rather 
inflexible software with limited capabilities. This is due to the fact that the cytometer has been 
designed and marketed as an instrument specific to a few particular assays, not as a multi-
purpose cytometer. 
The NASA-JSC Center Directors Discretionary Fund has funded the Cell & Molecular Research 
Laboratory to: (1) construct a prototype flight instrument based on the framework of the 
commercial cytometer; (2) perform ground-based and microgravity validation of the instrument; 
(3) design and validate a set of medical assays compatible with the prototype instrument; (4) 
design and validate a microgravity compatible cell staining device for sample processing that can 
interface with the instrument. In FY04 the initial stages of instrument design and validation were 
successfully completed, as well as the development of the cell staining unit and medical assays. 
The FY04 KC-135 evaluations that took place were as follows: 
Flight #1 6-29-2004 Validation of fluidics/function, standard sample acquisition 
Flight #2 8-10-2004 Std. Data acquisition, evaluation of precision sample delivery 
pipettes 
Flight #3 8-11-2004 Initial evaluation of new cell staining unit and associated 
instrument port 
Flight #4 9-2-2004 Complete blood-to-data system evaluation part 1 
Flight #5 9-7-2004 Complete blood-to-data system evaluation part 2 
METHODS AND MATERIALS 
Blood donors. Whole blood samples were obtained from adult donors into ACD anticoagulant 
vacutainers. This includes the KC-135 flight experiment and all developmental work performed 
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 in preparation for the experiment. The subjects had been screened by the NASA-JSC Human 
Test Subject Facility for most major infectious diseases and were found to be in good health. 
Institutional Review Board (NASA-JSC) approval was obtained for this study and written 
informed consent was obtained from all subjects. 
Cell staining. A complete 2-color antibody panel was formulated to resolve most major 
leukocyte subsets yet remain within the limitations of the instrument. The cell populations 
resolved included: leukocyte subsets; T cells; B cells; NK cells; T cell subsets and activated T 
cells. Cell surface markers were stained prior to flight. For the bead-based cytometry samples 
either fluorescent calibration microspheres or linearity fluorescent microspheres were used. 
Flow cytometry analysis. For ground-based analysis, a Beckman-Coulter XL flow cytometer was 
configured as a reference cytometer for 3 parameter/2 color analysis so that it would mimic the 
function of the cytometer. Analysis was performed using the XL as a reference cytometer, 
ground-based control data was generated using the prototype flight cytometer. For data collection 
during microgravity the sampling apparatus of the cytometer was altered for ease of operation 
during parabolic flight. To ensure data collection occurred during microgravity only, samples 
were mixed and affixed to the sampling probe and the instrument was primed prior to the 
initiation of the microgravity phase. Priming took place during the 2g phase between parabolas. 
Data collection was initiated as the parabola was initiated and ended as the aircraft exited the 
parabola.  
RESULTS: 
In FY04 the basic configuration of the prototype flight cytometer was prepared, the associated 
cell-staining unit (interfaces with instrument) was developed and validated, the medical assay 
panel was developed and validated and microgravity evaluation of all hardware was successfully 
performed.  
Development of prototype instrument: The internal components of a novel commercial 
cytometer were used as a basis for development of the basic prototype flight cytometer. The basic 
prototype flight cytometer consists of the unit with the minimal alterations required for 
microgravity evaluation and further development. (An advanced prototype flight cytometer will 
be completed in year two of this project that will be completely re-engineered for optimum 
compatibility with on-board flight operations) The areas of the commercial cytometer that were 
deemed not microgravity compatible were modified. These included: (1) replacing the waste 
collection system with an inflatable Teflon bag fixed to a one-way check valve and (2) modifying 
the sample uptake port with 10cm of silicone peak tubing and an injection port. The newly 
developed injection port was designed to be compatible low-flow fluidics and compatible with 
the injection port of the cell staining unit. 
Development of cell staining unit/sample processing procedure: A novel cell staining unit was 
developed by the CMR Laboratory in 1996, and evaluated onboard the Shuttle on STS-71. This 
unit, the Whole Blood Staining Device (WBSD), consists of tubing separated into chambers with 
clips with an injection port at one end. By filling the chambers with staining reagents, a blood 
sample may be injected and processed during microgravity. The WBSD was initially considered 
and evaluated with the prototype flight cytometer. It was found, however that the hard tygon 
tubing unit body created a negative pressure that hindered the instrument from withdrawing 
sample. This effect was found to dramatically alter the capacity of the instrument to provide 
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 absolute cell counts. A novel second generation unit was designed that used a sterile low-
adherence collapsible Teflon bag, a Baxter Interlink Injection Site and Weland clips for chamber 
separation. This unit, (the WBSD2) interfaced perfectly with the instrument, provided reliable 
absolute counts and was found to be robust and reliable.  
To generate absolute counts it is necessary to deliver a precise volume of blood sample into the 
staining device. For this purpose a 100ul positive displacement pipette was used. Several types of 
blood collection tubes were evaluated, and a 4.0 ml EDTA Starsted monovette was found to have 
several distinct advantages: (1) they are plastic; (2) the top screws into place and is not held by 
vacuum; (3) they are without vacuum during storage, the user creates the vacuum at the time of 
sample collection; (4) they make excellent storage vessels if there is an unexpected delay in 
processing; (5) the port is thinner than a vacutainer, meaning that the plastic pipette tip may pass 
through and sharp needles are not required.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Development of medical assay panel: A panel of clinical laboratory hematology and 
immunology assays, important in infection and immunity, was developed to be compatible with 
the limitations of the Prototype Flight Cytometer. This assay panel was achievable within the 
two-color cytometry limit of the instrument and would provide critical medical information 
currently not available on-orbit. The developed and evaluated assays were as follows: white 
blood cell count, leukocyte differential, lymphocyte subsets, T cell subsets, activated T cell levels 
and DNA content. The two-color antibody matrix developed for these assays was as follows: 
Fluorescent 
Antibodies 
Lyse/Fix 
Reagent 
Diluent 
Buffer 
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Microgravity evaluation of instrument and associated hardware: The instrument, all associated 
hardware, and the panel of assays were all evaluated real-time in microgravity conditions 
onboard the KC-135 aircraft. The sample delivery/processing hardware was found to function 
well during microgravity conditions, in a manner comparable to ground operation. The operators 
noted that care needed to be exercised to prevent air bubbles in the liquid samples from skewing 
the volume of sample primed in the pipette for delivery. However, the clear-bore design of the 
precision 100ul positive-displacement pipette allowed for easy inspection of the sample. The 
WBSD2 units functioned extremely well during microgravity and the interface with the 
instrument was found to be simple and reliable.  
The Prototype Flight 
Cytometer bolted to 
the floor of the KC-
135 aircraft for 
microgravity 
evaluation (left) and 
evaluation of the 
precision sample 
delivery and cell 
staining hardware 
PE PC5
CD14 CD45 WBC Differential: granulocytes/lymphocytes/monocytes.
CD3 CD45 T cell percentage
CD19 CD45 B cell percentage
CD16 CD45 NK cell percentage
CD3 CD4 Helper inducer T cell subsets
CD3 CD8 Cytotoxic/suppressor t cell subsets
CD45RO CD4 T cell subsets; memory/naïve T cell subsets
CD45R0 CD8 T cell subsets; memory/naïve T cell subsets
CD69 CD3 Activated T cell subsets.
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 The cytometer itself was found to function well in microgravity condition. Due to the sample 
priming delay caused by the temporary addition of the exterior peak tubing to which the WBSD 
sample port was attached, the operators had to begin priming the samples during the 2g phase of 
flight; however data were only collected during the microgravity phase. All peripheral blood 
leukocyte subset data collected during microgravity were found to be essentially identical to 
ground data and reference cytometer control data.  
DISCUSSION: 
The flow cytometer is an extremely versatile laboratory instrument with a broad-spectrum of uses 
in both clinical medicine and basic science research. It is therefore highly desirable to develop a 
spaceflight compatible cytometer for use on the International Space Station. While currently 
limited in ability, the cytometer represents an attractive design option for the design of a 
spaceflight compatible flow cytometer. It has the potential to be made completely microgravity 
compatible and serve as a prototype spaceflight instrument with relatively minimal alterations in 
design specifications.  
The cytometer’s level of miniaturization, use of a low energy diode laser, and elimination of the 
sheath fluid requirement all uniquely meet the existing prerequisites for use during spaceflight. It 
is likely that the current limitations of this instrument could be overcome by modifying the 
software, adding additional lasers, color PMTs, side scatter, color compensation ability and 
further miniaturization. The sample delivery apparatus of the cytometer is not microgravity 
compatible and would require significant modifications. These limitations notwithstanding, the 
cytometer may be well suited to be the prototype from which a spaceflight compatible flow 
cytometer is designed.  
The successful microgravity evaluation of the cytometer and the need to collect real-time 
experimental data onboard ISS for both research and clinical diagnosis purposes warrant the 
continued development of a spaceflight prototype flow cytometer. The versatility of the flow 
cytometer for general research (biological, microbial, environmental and physiological studies) 
and diagnostic medicine would be a major asset to the ISS/lunar/mars programs. 
CONCLUSION:  
A basic evaluation version of a prototype spaceflight-compatible flow cytometer was 
successfully created and evaluated. An associated sample processing system that interfaces with 
the instrument was also successfully developed.  
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 PHOTOGRAPHS: 
JSC2004E27340 
JSC2004E27342 
JSC2004E27347 to JSC2004E27349 
JSC2004E27372 to JSC2004E27375 
JSC2004E35188 
JSC2004E35197 to JSC2004E35203 
JSC2004E35218 to JSC2004E35227 
JSC2004E35238 
JSC2004E35293 
JSC2004E35652 to JSC2004E35673 
JSC2004E40306 to JSC2004E40320 
JSC2004E40641 to JSC2004E40659 
VIDEO: 
• Zero-g June 29 – July 2, 2004, Reference Master: 718394 
• Zero-g August 9 – 13, 2004, Reference Master: 718620 
• Zero-g August 30 – September 9, 2004, Reference Master: 718586 
Videos available from Imagery and Publications Office (GS4), NASA/JSC. 
CONTACT INFORMATION: 
Brian Crucian, Ph.D. 
Wyle Life Sciences 
1290 Hercules, Suite 120 
Houston, Texas 77058 
281-483-7061 
brian.crucian1@jsc.nasa.gov 
